Volume 23, Issue 1, Pages (April 2018)

Slides:



Advertisements
Similar presentations
Volume 14, Issue 3, Pages (January 2016)
Advertisements

Volume 20, Issue 6, Pages (December 2011)
Molecular Therapy - Nucleic Acids
Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma  Kuang-Tzu Huang, I-Ying Kuo, Ming-Chao.
Volume 21, Issue 12, Pages (December 2017)
Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma  Jia Wang, Tong Yang, Gaofeng Xu, Hao Liu, Chunying.
Mira Park, Ph. D. , Dae-Shik Suh, M. D. , Kangseok Lee, Ph. D
SNEVhPrp19/hPso4 Regulates Adipogenesis of Human Adipose Stromal Cells
Volume 53, Issue 4, Pages (February 2014)
MicroRNA-489 Plays an Anti-Metastatic Role in Human Hepatocellular Carcinoma by Targeting Matrix Metalloproteinase-7  Yixiong Lin, Jianjun Liu, Yuqi Huang,
Volume 9, Issue 5, Pages (November 2017)
Volume 14, Issue 3, Pages (January 2016)
Volume 13, Issue 3, Pages (October 2015)
PPARγ signaling correlates with LATS2 in human and mouse tumors and promotes cell death in a LATS2-dependent manner. PPARγ signaling correlates with LATS2.
SMARCAD1 Phosphorylation and Ubiquitination Are Required for Resection during DNA Double-Strand Break Repair  Sharmistha Chakraborty, Raj K. Pandita,
Volume 140, Issue 1, Pages (January 2011)
Volume 6, Issue 5, Pages (March 2014)
Volume 165, Issue 1, Pages (March 2016)
Volume 15, Issue 3, Pages (April 2016)
Feng Zhang, Jiazhong Shi, Chunjing Bian, Xiaochun Yu  Cell Reports 
Volume 67, Issue 3, Pages e5 (August 2017)
(A) Schematic representation of the conditional Lats1 locus.
A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2  Katharina Schlacher, Hong Wu, Maria Jasin 
Volume 46, Issue 2, Pages (April 2012)
Volume 68, Issue 2, Pages e8 (October 2017)
Molecular Therapy - Nucleic Acids
Volume 4, Issue 3, Pages (August 2013)
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Volume 19, Issue 10, Pages (June 2017)
Volume 156, Issue 4, Pages e8 (March 2019)
Volume 20, Issue 6, Pages (December 2011)
Volume 21, Issue 12, Pages (December 2017)
Volume 54, Issue 3, Pages (May 2014)
Molecular Mechanisms Regulating the Defects in Fragile X Syndrome Neurons Derived from Human Pluripotent Stem Cells  Tomer Halevy, Christian Czech, Nissim.
Volume 23, Issue 3, Pages (April 2018)
Volume 16, Issue 1, Pages (June 2016)
Volume 4, Issue 3, Pages (March 2015)
SUMO-2 Orchestrates Chromatin Modifiers in Response to DNA Damage
Volume 19, Issue 11, Pages (June 2017)
Volume 25, Issue 8, Pages e4 (November 2018)
Volume 66, Issue 4, Pages e5 (May 2017)
Volume 5, Issue 6, Pages (December 2013)
Volume 66, Issue 2, Pages e9 (April 2017)
Kun-Peng Zhu, Xiao-Long Ma, Chun-Lin Zhang  Molecular Therapy 
SUMO-2 Orchestrates Chromatin Modifiers in Response to DNA Damage
Volume 18, Issue 6, Pages (December 2015)
Volume 10, Issue 2, Pages (January 2015)
Volume 62, Issue 6, Pages (June 2016)
Volume 23, Issue 5, Pages (May 2013)
Volume 12, Issue 4, Pages (July 2015)
Volume 15, Issue 12, Pages (June 2016)
Negative Regulation of Tumor Suppressor p53 by MicroRNA miR-504
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Volume 167, Issue 2, Pages e9 (October 2016)
Volume 24, Issue 18, Pages (September 2014)
Volume 22, Issue 4, Pages (January 2018)
Volume 14, Issue 11, Pages (March 2016)
Volume 26, Issue 12, Pages e4 (March 2019)
Overexpression of IL-27 upregulates expression of multiple IR by T cells in vivo. Overexpression of IL-27 upregulates expression of multiple IR by T cells.
Molecular Therapy - Nucleic Acids
Volume 15, Issue 11, Pages (June 2016)
Volume 12, Issue 4, Pages (April 2019)
Circular RNA Transcriptomic Analysis of Primary Human Brain Microvascular Endothelial Cells Infected with Meningitic Escherichia coli  Ruicheng Yang,
Volume 13, Issue 1, Pages (October 2015)
Volume 26, Issue 11, Pages e6 (March 2019)
Volume 71, Issue 1, Pages e6 (July 2018)
Volume 13, Issue 11, Pages (December 2015)
NUAK1 overexpression correlates with tumor progression, lymph node infiltrates, and reduced overall survival (OS) in human colorectal cancer. NUAK1 overexpression.
Volume 24, Issue 12, Pages e4 (September 2018)
Volume 15, Issue 4, Pages (April 2016)
Presentation transcript:

Volume 23, Issue 1, Pages 100-111 (April 2018) Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas  Khyati Meghani, Walker Fuchs, Alexandre Detappe, Pascal Drané, Ewa Gogola, Sven Rottenberg, Jos Jonkers, Ursula Matulonis, Elizabeth M. Swisher, Panagiotis A. Konstantinopoulos, Dipanjan Chowdhury  Cell Reports  Volume 23, Issue 1, Pages 100-111 (April 2018) DOI: 10.1016/j.celrep.2018.03.038 Copyright © 2018 The Author(s) Terms and Conditions

Cell Reports 2018 23, 100-111DOI: (10.1016/j.celrep.2018.03.038) Copyright © 2018 The Author(s) Terms and Conditions

Figure 1 Expression of miR-493-5p Correlates with Platinum-Resistant/Refractory Disease Specifically in BRCA2 Mutant Ovarian Carcinomas (A) Volcano plot representing differentially expressed miRNAs in platinum-sensitive versus platinum-resistant/refractory carcinomas. x axis represents mean difference in miRNA expression (sensitive versus resistant), and y axis represents ANOVA p value (−log10). (B) Overall survival (OS) for patients with BRCA1- or BRCA2-mutated ovarian carcinomas based on above or below median expression values of miR-493-5p. Left panel denotes overall survival for BRCA1-mutated tumors. Right panel denotes overall survival for BRCA2-mutated tumors. Statistical significance was assessed by the log rank test. (C) Progression-free survival (PFS) for patients with BRCA1- or BRCA2-mutated HGSOCs based on quartile cutoff expression values of miR-493-5p. Left panel denotes progression-free survival for BRCA1-mutated carcinomas. Right panel denotes progression-free survival for BRCA2-mutated carcinomas. Statistical significance was assessed by the log rank test. For all panels, n.s. represents p value > 0.05, ∗p value < 0.05, ∗∗p value < 0.01, ∗∗∗p value < 0.001, and ∗∗∗∗p value < 0.0001. See also Figure S1. Cell Reports 2018 23, 100-111DOI: (10.1016/j.celrep.2018.03.038) Copyright © 2018 The Author(s) Terms and Conditions

Figure 2 Expression of miR-493-5p Causes PARPi and Platinum Resistance in BRCA2 Mutant Cells In Vitro and In Vivo (A) Survival assays to examine the impact of miR-493-5p overexpression in BRCA2 mutant KURAMOCHI, OVSAHO, and VU423 cells exposed to the indicated DNA-damaging agents. (B) Survival assays to examine the impact of miR-493-5p overexpression in BRCA1 mutant COV362 and UWB1.289 cells exposed to the indicated DNA-damaging agents. (C) Schematic for KB2P (p53−/− Brca2−/− mouse model) PARPi intervention study. (D) miR-493-5p expression levels in matched PARPi-naive and resistant KB2P p53−/− Brca2−/− mammary mouse models (derived from independent spontaneous tumor donors). Expression was normalized using U6SnRNA as reference. For all panels, data are represented as mean ± SEM from three different experiments, n.s. represents p value > 0.05, ∗p value < 0.05, ∗∗p value < 0.01, ∗∗∗p value < 0.001, and ∗∗∗∗p value < 0.0001. See also Figure S2. Cell Reports 2018 23, 100-111DOI: (10.1016/j.celrep.2018.03.038) Copyright © 2018 The Author(s) Terms and Conditions

Figure 3 miR-493-5p Significantly Downregulates Expression of Multiple Genes Involved in Genomic Stability (A) Volcano plot depicting differentially expressed genes in control-miR versus miR-493-5p-overexpressing Kuramochi cells. x axis represents log2 expression fold change in control-miR versus miR-493-5p-mimic-transfected cells, and the y axis represents ANOVA p value (−log10). (B) Quadrant-based segregation to identify genes that are significantly differentially expressed in the microarray and significantly correlate to levels of miR-493-5p in BRCA2-mutated carcinomas in the TCGA dataset. Highlighted quadrant four represents 245 genes that are significantly downregulated in the microarray and correlate significantly to miR-493-5p levels in the TCGA cohort of 34 BRCA2-mutated tumors. (C) Quantification of protein levels in miR-493-5p-transfected cells normalized to control-miR-transfected cells. For (C), data are represented as mean ± SEM from two different experiments, n.s. represents p value > 0.05, ∗p value < 0.05, ∗∗p value < 0.01, ∗∗∗p value < 0.001, and ∗∗∗∗p value < 0.0001. See also Figure S3. Cell Reports 2018 23, 100-111DOI: (10.1016/j.celrep.2018.03.038) Copyright © 2018 The Author(s) Terms and Conditions

Figure 4 miR-493-5p Has an Impact on SSA, DNA Replication Fork Stability in BRCA2 Mutant, or Depleted Cells (A) DR-GFP, SA-GFP, EJ-2, and EJ-5 assay in U2OS cells transfected with indicated siRNA or miRNA. (B) Quantification of Rad51 foci dynamics in U2OS cells transfected with the indicated miRNA. (C) Quantification of Rad52 foci dynamics in VU423 cells stably expressing mCherry-Rad52 reporter transfected with the indicated miRNA. (D) Quantification of Idu/Cldu lengths in Kuramochi cells transfected with control-miR or miR-493-5p mimics with or without hydroxyurea treatment (left panel). Schematic of labeling cells with Cldu and Idu to study replication fork degradation (right panel) is shown. For all panels, data are represented as mean ± SEM from three different experiments, n.s. represents p value > 0.05, ∗p value < 0.05, ∗∗p value < 0.01, ∗∗∗p value < 0.001, and ∗∗∗∗p value < 0.0001. See also Figure S4. Cell Reports 2018 23, 100-111DOI: (10.1016/j.celrep.2018.03.038) Copyright © 2018 The Author(s) Terms and Conditions

Figure 5 miR-493-5p Has an Impact on Pathways Regulating R-Loop Processing and Ribonucleotide Excision Repair Pathway (A) Plot showing correlation of miR-493-5p with different pathways. (B) Quantification of R-loops measured as S9.6 intensity in BRCA2 mutant VU423 cells transfected with control-miR or miR-493-5p post-transfection with RNaseH1-GFP. (C) Survival assays to assess the impact of BRCA2 mutant Kuramochi, OVSAHO, and VU423 cells transfected with the indicated siRNA and treated with the indicated DNA-damaging agents. (D) Progression-free survival for BRCA2-mutated HGSOC in the TCGA dataset segregated based on the median expression levels of RNASEH2A, SSRP1, and FEN1. Statistical significance was assessed by the log rank test. For Figures 5B and 5C, data are represented as mean ± SEM from three different experiments, n.s. represents p value > 0.05, ∗p value < 0.05, ∗∗p value < 0.01, ∗∗∗p value < 0.001, and ∗∗∗∗p value < 0.0001. See also Figure S5. Cell Reports 2018 23, 100-111DOI: (10.1016/j.celrep.2018.03.038) Copyright © 2018 The Author(s) Terms and Conditions